BioTuesdays
Titan Pharmaceuticals Logo

Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine. The move was part of several announced by the...

Can-Fite Logo

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

Titan Pharmaceuticals Logo

Titan Pharma added to Russell 3000 index

Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective...

oramed

OrbiMed joins Round B NovellusDx financing

OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

oramed

Oramed gets milestone payment from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s...

Titan Pharmaceuticals Logo

Titan Pharma gains more media attention

NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine...

Juniper Pharmaceuticals

Juniper Pharma COL-1077 Phase 1 data published

The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and...

Aegerion

QLT and Aegerion Pharma to merge

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics. Under the accord, each outstanding...